A phase 1b study of MABS-139 in selected tumor indications
Latest Information Update: 23 May 2023
At a glance
- Drugs MABS-139 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 23 May 2023 New trial record
- 15 May 2023 According to a Manhattan BioSolutions media release, the company plans to initiate this study after completing the investigational new drug (IND) application process.